Who are Vistagen Therapeutics, Inc.'s main suppliers?

Vistagen Therapeutics, Inc. (VTGN) key suppliers include: Johnson & Johnson, Johnson & Johnson, Eli Lilly and Company, Eli Lilly and Company, ORANY and 1 more. View the full supplier network at chainsifter.com/chain/VTGN.

Who are Vistagen Therapeutics, Inc.'s major customers?

Vistagen Therapeutics, Inc. (VTGN) key customers include: Johnson & Johnson, Johnson & Johnson, Eli Lilly and Company, Eli Lilly and Company, ORANY and 1 more. View the full customer network at chainsifter.com/chain/VTGN.

What sector is Vistagen Therapeutics, Inc. in?

Vistagen Therapeutics, Inc. (VTGN) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

VTGN Supply Chain: Vistagen Therapeutics, Inc. Supplier List & 15 Relationships

6Suppliers

6Customers

3Debt Items

20Related Chains

Vistagen Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
JNJ	Johnson & Johnson	72%	ceived from Fuji Pharma a payment of $1.5 million (Purchase Price). The Purchase Price is non-refundable, except upon a material breach of the Negotiation Agreement by us, however, should we and Fuji…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from VTGN graph: ceived from Fuji Pharma a payment of $1.5 million (Purchase Price). The Purchase Price is non-refundable, except upon …
LLY	Eli Lilly and Company	72%	ceived from Fuji Pharma a payment of $1.5 million (Purchase Price). The Purchase Price is non-refundable, except upon a material breach of the Negotiation Agreement by us, however, should we and Fuji…
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from VTGN graph: ceived from Fuji Pharma a payment of $1.5 million (Purchase Price). The Purchase Price is non-refundable, except upon …
ORANY	ORANY	72%	of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before administrative bodies in the U.S. or a…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from VTGN graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from VTGN graph: of the patent withheld relevant i…

Vistagen Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
JNJ	Johnson & Johnson	72%	ceived from Fuji Pharma a payment of $1.5 million (Purchase Price). The Purchase Price is non-refundable, except upon a material breach of the Negotiation Agreement by us, however, should we and Fuji…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from VTGN graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from VTGN graph: Reciprocal relationship from JNJ grap…
LLY	Eli Lilly and Company	72%	ceived from Fuji Pharma a payment of $1.5 million (Purchase Price). The Purchase Price is non-refundable, except upon a material breach of the Negotiation Agreement by us, however, should we and Fuji…
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from VTGN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from VTGN graph: ceived from Fuji Pharma a payment of …
ORANY	ORANY	72%	al of completing its review of 90% of all applications within ten months from the submission receipt date. Such deadlines are referred to as the PDUFA date. The review process and the PDUFA goal date…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from VTGN graph: al of completing its review of 90% of all applications within ten months from the submission receipt date. Such dead…

Vistagen Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
VTGN-DEBT	Debt stack $1.4M	90%	Market cache reports total debt of $1.4M.
VTGN-DEBT-13458	Warrants outstanding: 9275858	90%	xbrl warrant detail from xbrl 2025-07-31.
VTGN-DEBT-13459	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2017-03-31.

Vistagen Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Vistagen Therapeutics, Inc..

Vistagen Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
VTGN-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC	VANGUARD CAPITAL MANAGEMENT LLC	90%	13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 59 tracked holders.

Vistagen Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
LLY	Eli Lilly and Company	100.00	1	['customer', 'supplier']
JNJ	Johnson & Johnson	100.00	1	['customer', 'supplier']
ORANY	ORANGE	100.00	1	['customer', 'supplier']
BLTE	Belite Bio, Inc	50.00	2
CYCN	Cyclerion Therapeutics, Inc.	50.00	2
CPRX	Catalyst Pharmaceuticals, Inc.	50.00	2
AMZE	Amaze Holdings, Inc.	50.00	2
CYTOF	Altamira Therapeutics Ltd.	50.00	2
AYTU	Aytu BioPharma, Inc.	50.00	2
CTNM	Contineum Therapeutics, Inc.	50.00	2
ANIK	Anika Therapeutics, Inc.	50.00	2
D	Dominion Energy, Inc.	50.00	2
DAWN	Day One Biopharmaceuticals Inc	50.00	2
AXSM	Axsome Therapeutics, Inc.	50.00	2
AORT	Artivion, Inc.	50.00	2
DARE	Daré Bioscience, Inc.	50.00	2
AVBP	ArriVent BioPharma, Inc.	50.00	2
CANF	Can-Fite BioPharma Ltd.	50.00	2
DFTX	Definium Therapeutics, Inc.	50.00	2
CVRX	CVRx, Inc.	50.00	2

Vistagen Therapeutics, Inc. Supply Chain